Trial Profile

A Phase 2, Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Contezolid Acefosamil Compared to Linezolid Administered Intravenously and Orally to Adult Subjects With Acute Bacterial Skin and Skin Structure Infection

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 09 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Contezolid-acefosamil (Primary) ; Contezolid-acefosamil (Primary) ; Linezolid; Linezolid
Indications Cellulitis; Erysipelas; Gram-positive infections; Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections; Vancomycin-resistant enterococcal infections; Wound infections
Focus Therapeutic Use
Sponsors MicuRx Pharmaceuticals

13 Jul 2020 Status changed from recruiting to completed.
09 Sep 2019 Primary endpoint has been met. (Early clinical response in the ITT population)
09 Sep 2019 Top-line results published in the MicuRx Pharmaceuticals Media Release

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com